Development of anti-AAV assay for detection of pre-existing AAV immunity
Apr
18
2023
On demand

Development of anti-AAV assay for detection of pre-existing AAV immunity

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Sponsor
Development of anti-AAV assay for detection of pre-existing AAV immunity

AAV vectors are used in gene therapy products for treatment of genetic diseases. The high natural prevalence of AAV wild-type viruses has resulted in a high frequency of capsid-directed humoral immunity in human populations and many animal models, which may interfere with the therapeutic efficiency of a therapy if not identified and managed properly.

This case study describes the development of an anti-AAV immune assay for use in preclinical studies using cynomolgus monkeys, with the ability to screen for pre-existing AAV immunity and to identify low-responding individuals to maximize the likelihood of successful transduction.

  • Importance of pre-screening for existing AAV immunity to maximize results of clinical/pre-clinical studies
  • Development of anti-AAV immunoassay using an automated immunoassay platform
Zhe Liu
Zhe Liu
Staff Scientist, Labcorp Early Development
John Chappell
John Chappell
Director of Scientific Support, EMEA and Asia Pacific, Gyros Protein Technologies

 

John Chappell has approximately 25 years of experience in the Contract Research industry supporting both preclinical and clinical drug development. He has specialized in supporting biological compounds from an analytical perspective e.g. Pharmacokinetic, Immunogenicity and Biomarker analysis. He is particularly interested in validation requirements and ensuring that data generated will be acceptable to the regulatory authorities.

He has spoken at many international conferences on various topics including Oligonucleotide analysis, Biomarker Analysis, Immunogenicity and the analytical support of Biosimilar programs. He now leads the Application Support and Service teams for Gyros where he is responsible for customer service and technical support in Europe and the Asia Pacific regions. John has been a user of the Gyros system for over 10 years so will use this experience to help customers.

He is a Fellow of the Royal Society of Chemistry and was involved in the American Association of Pharmaceutical Scientists (AAPS) Biosimilar Committee that has prepared papers on Pharmacokinetic and anti-drug antibody assays.

 

SPEAKERS

Zhe Liu
Zhe Liu
Staff Scientist, Labcorp Early Development
John Chappell
John Chappell
Director of Scientific Support, EMEA and Asia Pacific, Gyros Protein Technologies